Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours

Background: This Phase I study evaluated continuous- and intermittent-dosing (every other week) of afatinib plus nintedanib in patients with advanced solid tumours. Methods: In the dose-escalation phase (n=45), maximum tolerated doses (MTDs) were determined for continuous/intermittent afatinib 10, 20, 30 or 40 mg once daily plus continuous nintedanib 150 or 200 mg twice daily. Secondary objectives included safety and efficacy. Clinical activity of continuous afatinib plus nintedanib at the MTD was further evaluated in an expansion phase (n=25). Results: The most frequent dose-limiting toxicities were diarrhoea (11%) and transaminase elevations (7%). Maximum tolerated doses were afatinib 30 mg continuously plus nintedanib 150 mg, and afatinib 40 mg intermittently plus nintedanib 150 mg. Treatment-related adverse events (mostly Grade ⩽3) included diarrhoea (98%), asthenia (64%), nausea (62%) and vomiting (60%). In the dose-escalation phase, two patients had partial responses (PRs) and 27 (60%) had stable disease (SD). In the expansion phase, one complete response and three PRs were observed (all non-small cell lung cancer), with SD in 13 (52%) patients. No pharmacokinetic interactions were observed. Conclusions: MTDs of continuous or intermittent afatinib plus nintedanib demonstrated a manageable safety profile with proactive management of diarrhoea. Antitumour activity was observed in patients with solid tumours.

Cancer cells exhibit dysregulation of multiple signalling pathways that facilitate tumour growth and progression and often demonstrate a certain degree of cross-talk (Tabernero, 2007;Larsen et al, 2011). Members of the ErbB receptor family, including epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor (HER2/ErbB2), ErbB3 (HER3) and ErbB4 (HER4), have important roles in cell proliferation, migration and apoptosis, and have been implicated in a variety of malignancies (Yarden and Pines, 2012). Vascular endothelial growth factor (VEGF), a key regulator in angiogenesis, also has an important role in tumour growth and metastasis (Tabernero, 2007), and expression levels of VEGF and VEGF receptors (VEGFRs) have been correlated with poor outcomes in numerous tumour types (Goel and Mercurio, 2013).
Several agents that individually target the EGFR or VEGFR pathways have been approved for the treatment of cancer, particularly non-small cell lung cancer (NSCLC); however, longterm efficacy of these agents as monotherapies is limited and resistance often occurs (Tabernero, 2007;Domvri et al, 2013). In *Correspondence: Professor J-C Soria; E-mail: soria@igr.fr Presented, in part, at the European Society for Medical Oncology congress, 28 September-02 October 2012, Vienna,Austria. Abstract No. 979. this context, preclinical models suggest that resistance to EGFRtargeted agents can be associated with increased VEGF expression, and combined EGFR/VEGR pathway blockade can abrogate this resistance (Naumov et al, 2009). The commonality and cross-talk between these two prominent signalling pathways provides biological rationale for combined EGFR/VEGF pathway-targeted therapy. This rationale was tested in a Phase III trial in NSCLC patients, wherein the combination of bevacizumab, an anti-VEGF monoclonal antibody, and the reversible EGFR tyrosine kinase inhibitor (TKI) erlotinib was compared with erlotinib monotherapy (Herbst et al, 2011). The combination appeared to improve objective response and progression-free survival (PFS) vs erlotinib alone, although without an overall survival benefit.
Afatinib is an oral, irreversible ErbB family blocker that inhibits signalling from all ErbB receptor homo-and heterodimers (Li et al, 2008;Solca et al, 2012). On the basis of significant improvements in PFS vs standard platinum-based chemotherapy in two pivotal Phase III studies (Sequist et al, 2013;Wu et al, 2014), afatinib (40 mg, once daily (QD)) was approved in the USA, EU and Japan for the treatment of patients with NSCLC harbouring distinct types of EGFR mutations (European Medicines Agency, 2013;Food and Drug Administration, 2013;Pharmaceuticals and Medical Devices Agency Japan, 2013). Nintedanib is an oral triple angiokinase inhibitor of VEGFR-1, 2 and 3, platelet-derived growth factor receptor (PDGFR) a and b, and fibroblast growth factor receptor (FGFR) 1, 2 and 3 (Hilberg et al, 2008). Nintedanib (200 mg, twice daily (BID)) is approved in the EU in combination with docetaxel for second-line treatment of patients with advanced NSCLC of adenocarcinoma histology (European Medicines Agency, 2015), and in the USA and EU for the treatment of patients with idiopathic pulmonary fibrosis (at a dose of 150 mg BID) (European Medicines Agency, 2014;Food and Drug Administration, 2014). The combination of afatinib and nintedanib has been evaluated in preclinical studies and early phase clinical trials in advanced solid tumours. In preclinical models of head and neck squamous cell carcinoma (HNSCC) and colorectal cancer, the combination of afatinib plus nintedanib demonstrated greater inhibition of cell proliferation and xenograft tumour growth compared with either single agent (Solca et al, 2007;Poindessous et al, 2011). In two Phase II studies investigating sequential combination of afatinib and nintedanib in patients with advanced colorectal cancer or castration-resistant prostate cancer, the combination treatment was associated with expected and manageable safety profiles but showed limited antitumour activity (Bouche et al, 2011;Molife et al, 2014). It was speculated that more intensive, continuous dosing may provide greater efficacy and would be feasible based on the manageable safety findings (Bouche et al, 2011).
On the basis of the aforementioned clinical studies, new dosing schedules were devised for afatinib, administered either continuously or intermittently, in combination with continuous nintedanib. This Phase I study, which evaluated the new dosing schedules in patients with advanced solid tumours, consisted of two parts: a dose-escalation phase and an expansion phase (ClinicalTrials.gov Identifier: NCT00998296; 1239.14). The dose-escalation phase was conducted to evaluate the safety and maximum tolerated dose (MTD) of the combination dosing schedules. The expansion phase investigated the safety and preliminary antitumour activity of the combination at the MTD in a concomitant, continuous treatment schedule in patients with NSCLC or pancreatic adenocarcinoma.

MATERIALS AND METHODS
Patients. Patients were X18 years of age, with confirmed diagnosis of advanced solid tumours not amenable to established treatments, a life expectancy of X3 months, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Additional inclusion criteria included adequate organ function with no significant gastrointestinal tract or cardiovascular disease, pre-existing interstitial lung disease, active infective disease, or untreated or symptomatic brain metastases. Patients were excluded if they had received chemotherapy, immunotherapy, radiotherapy (small-field palliative radiotherapy was allowed), hormone therapy (except for breast or prostate cancer treatment), prior EGFR-or HER2-inhibiting drugs, an anti-angiogenic agent, or any other investigational drugs within 4 weeks prior to screening; had a history of haemorrhagic or thrombotic events within the last 6 months; or current Grade 1 or higher peripheral neuropathy unless due to trauma. No anticoagulation therapy, except low-dose heparin and/or heparin flush, was allowed.
The study was conducted in accordance with the Declaration of Helsinki, local laws and the International Conference on Harmonisation Good Clinical Practice Guideline, and approved by the relevant regulatory authority (Agence Nationale de Sécurité du Médicament et des Produits de Sante [ANSM], France) and an independent ethics committee (Comité de Protection des Personnes Ile de France X, Hôpital Robert Ballanger, France). All patients provided written informed consent for participation in the trial.
Study design and treatments. This was a single-centre (France), open-label, Phase I study consisting of a dose-escalation phase and an expansion phase. The dose-escalation phase consisted of a modified 3 þ 3 design with two schedules of afatinib in combination with nintedanib. Patients received 10, 20, 30 or 40 mg afatinib QD, following a continuous or intermittent schedule (every other week), in combination with continuous nintedanib (150 or 200 mg BID) for a 28-day treatment cycle. Dose-escalation started with 10 mg of afatinib QD administered continuously. If after 28 days fewer than two patients had experienced dose-limiting toxicities (DLTs), a new cohort at the next dose level was started. Each cohort consisted of at least three patients. Dose escalation of continuous afatinib continued until observation of DLTs in two or more patients during the first 28-day cycle; the same dose level was then explored for the intermittent afatinib schedule. Nintedanib was initially administered at a fixed dose of 200 mg BID; however, due to excess DLTs no MTD was determined. Following a protocol amendment, the nintedanib dose was reduced to 150 mg BID and a second dose-escalation phase was conducted starting with afatinib 30 mg QD.
In the expansion phase, treatment of two additional cohorts of patients with NSCLC or pancreatic adenocarcinoma was initiated at the MTD for concomitant afatinib plus nintedanib therapy determined in the dose-escalation phase. Treatment continued for as long as tolerable and no progressive disease (PD) was observed.
Endpoints and assessments. The primary endpoint of the doseescalation phase was to determine the MTD of the afatinib and nintedanib combination, defined as the highest doses of afatinib (continuous or intermittent) and nintedanib at which fewer than two of six treated patients experienced a DLT during the first 28-day treatment cycle. Exploratory secondary endpoints for the doseescalation phase included safety, objective response according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1, pharmacokinetic (PK) assessments and numbers of circulating tumour cells (CTCs). The primary endpoints of the expansion phase were to assess the safety and preliminary antitumour activity of concomitant afatinib plus nintedanib at the previously determined MTD in patients with NSCLC or pancreatic adenocarcinoma.
Safety was assessed by incidence and intensity of adverse events (AEs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (http://ctep.cancer.gov/protocolDevelopment/electronic_ applications/ctc.htm). Recommendations for afatinib or nintedanib dose interruptions and reductions were provided to effectively manage specific treatment-related AEs. In the event of any treatment-related Grade X3 AE, Grade X2 diarrhoea persisting for X2 consecutive days despite supportive care (i.e., treatment with antidiarrhoeal medication and hydration) or Grade X3 diarrhoea despite supportive care, treatment with afatinib was interrupted until recovery to Grade p1 or baseline (i.e., resolution to at least the patient's pretherapy value at study enrolment). In the event of treatment-related Grade X3 aspartate aminotransferase (AST) and/ or alanine aminotransferase (ALT) elevations or Grade X2 elevation in conjunction with Grade X1 bilirubin elevation, treatment with nintedanib was interrupted until recovery to baseline. Once recovered, patients could continue treatment with the assigned study medication following recommended dose reductions, depending on the starting dose. For patients receiving afatinib 30 or 40 mg QD, 10-mg dose reductions to a minimum of 20 mg QD were allowed; treatment was discontinued in case of further AEs at 20 mg QD. Afatinib 10 and 20 mg QD starting doses were not reduced but given intermittently; treatment was discontinued in case of further AEs. Nintedanib doses were reduced by 50-mg decrements to a minimum of 100 mg BID (from an initial dose of 200 mg BID) or 50 mg BID (from an initial dose of 150 mg BID); treatment was discontinued in case of further AEs.
Treatment-related AEs defined as DLTs per protocol included: uncomplicated Grade 4 neutropenia for 47 days; Grade 3/4 neutropenia of any duration associated with fever 438.5 1C; platelets o25 000 per ml or Grade 3 thrombocytopenia associated with bleeding requiring transfusion; Grade X3 non-haematological toxicity (except nausea, vomiting or diarrhoea if managed with appropriate medical care, and alkaline phosphatase (ALP) o10 Â the upper limit of normal (ULN) in patients with Grade 2 ALP (42.5-5 Â ULN) at baseline due to bone or liver metastases); Grade X2 decrease in cardiac left ventricular function, worsening of renal function, or diarrhoea, vomiting or nausea persisting for X7 days, despite supportive care; treatment-related liver toxicity except gamma glutamyltransferase elevation (AST/ALT/ALP 45 Â ULN if total bilirubin p1.5 Â ULN or AST/ALT/ALP 42.5 Â ULN if associated with total bilirubin 41.5 Â ULN); Grade X2 DLTs leading to an interruption of both drugs for X14 consecutive days. For any patient with a DLT, treatment was stopped until the AE resolved to Grade p1 or baseline. Once recovered, patients who had a documented clinical benefit (absence of disease progression) were eligible for further treatment with the assigned study medication following recommendations for dose reduction, as described above.
Tumour assessments by computed tomography or magnetic resonance imaging were performed at screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment visit. Tumour response was evaluated according to RECIST (version 1.1). Investigators assigned one of the following categories to each patient: complete response (CR), partial response (PR), stable disease (SD), PD or not evaluable. Disease control rate ((DCR) including CR, PR and SD) was also assessed.
During the dose-escalation phase, PK assessments were conducted in all patients who took at least one dose of trial medication and provided at least one blood sample following drug administration. Samples (5 ml of venous blood) were collected immediately before the morning administration of treatment on Days 1,8,15,22,28,42 and 56. Afatinib and nintedanib drug concentrations were determined by validated high-performance liquid chromatography-tandem mass spectrometry.
For determination of CTCs, 7.5 ml blood samples were drawn in CellSave Blood Collection tubes (Veridex, Raritan, NJ, USA) at baseline and at Days 15, 30 and 60. Samples were analysed with CellSearch Circulating Tumour kit (Veridex, Raritan, NJ, USA) according to the manufacturer's instructions and reported as number of CTCs in 7.5 ml of blood. Patients were categorised as having unfavourable (X5 CTC/7.5 ml) or favourable (o5 CTC/ 7.5 ml) CTC counts, based on defined cut-offs from previous studies (Cristofanilli et al, 2004;de Bono et al, 2008).
Statistical analyses. The number of patients required to determine the MTD in the dose-escalation phase ranged from 3 to 45, depending on the dosage reached. In the expansion phase, a maximum of 12 patients were to be recruited for the pancreatic adenocarcinoma cohort, and a maximum of 18 patients were to be recruited for the NSCLC cohort. Assuming a 5% drop out rate, the estimated number of patients required for the study was up to 79.
All analyses are descriptive and exploratory. Data from the two afatinib dosing schedules in the dose-escalation phase were analysed separately. The treated analysis set included all patients who received at least one dose of afatinib or nintedanib during the study period. The MTD analysis set included all patients eligible for determination of MTD in the opinion of the investigator (reviewed by the Clinical Trial Monitor).

Patients.
A total of 45 patients were enroled in the dose-escalation phase from October 2009 to January 2012 (Table 1). The majority of patients had an ECOG performance status of 1 (69%) and had received at least four lines of prior anticancer therapy (73%). The most common cancer types were colorectal, NSCLC, ovary and breast.
Following the dose-escalation phase, 25 patients with NSCLC (n ¼ 18) or pancreatic adenocarcinoma (n ¼ 7) were enroled in the expansion phase (Table 1). The majority of patients with NSCLC were female (61%), whereas the majority of patients with pancreatic adenocarcinoma were male (86%). Among all patients in the expansion phase, 44% received at least four lines of prior anticancer therapy.
DLTs and determination of MTD in the dose-escalation phase. Dose escalation up to 40 mg afatinib QD was achieved for both intermittent and continuous schedules. Overall, there were 12 DLTs reported in seven patients receiving afatinib in a continuous schedule and five DLTs in four patients receiving afatinib in an intermittent schedule; the frequency and intensity of DLTs observed in each dose cohort are detailed in Table 2. The most frequent DLT was diarrhoea (five patients (11%)) followed by increased ALT, increased blood creatinine, dehydration, hepatocellular injury and acute renal failure (two patients (4%) each); DLTs of increased AST and hepatotoxicity occurred in one patient each. The maximum CTCAE grade reported for DLTs was Grade 3 for 10 patients and Grade 4 for one patient (hepatotoxicity in the nintedanib 200 mg BID plus afatinib 40 mg QD intermittent cohort). Two dose cohorts achieved six evaluable patients with no DLTs, therefore two MTDs were determined: nintedanib 150 mg BID plus afatinib 30 mg QD continuously, and nintedanib 150 mg BID plus afatinib 40 mg QD every other week. The continuous afatinib 30 mg QD plus nintedanib 150 mg BID schedule was chosen for further evaluation in the expansion phase of the trial, based on the findings from two Phase II studies demonstrating a lack of antitumour activity with intermittent afatinib plus nintedanib scheduling (Bouche et al, 2011;Molife et al, 2014).
Treatment duration. In the dose-escalation phase, median (range) exposure to afatinib and nintedanib in the continuous cohorts was 62.5 (7-239) days. In the intermittent cohorts, median exposure to afatinib and nintedanib was 53.0 (4-160) days and 60.0 (11-167) days, respectively. Eight patients discontinued treatment before the end of the first 28-day treatment cycle; two (4%) for progressive disease, five (11%) for DLT or dose-reducing toxicity, and one (2%) for Grade 3 diarrhoea.
Overall safety. In the dose-escalation phase, all patients experienced at least one AE, with treatment-related AEs occurring in 44 (98%) patients (Table 3). Most treatment-related AEs were Grade p3; no Grade 5 AEs were reported. Diarrhoea (98%), asthenia (64%), nausea (62%) and vomiting (60%) were the most frequently occurring treatment-related AEs. Eight patients (18%) had AEs that led to discontinuation of afatinib and nintedanib, and two patients had AEs that led to discontinuation of afatinib only (one receiving intermittent afatinib 40 mg QD and nintedanib 150 mg BID and one receiving intermittent afatinib 40 mg QD and nintedanib 200 mg BID). Serious AEs (SAEs) occurred in 26 patients (17 on continuous afatinib and 9 on intermittent afatinib). Among these patients, 15 (58%) had at least one SAE that was considered to be treatment-related. There were three deaths, all due to AEs that occurred post treatment (within 28 days following the last treatment administration). In the cohorts receiving the determined MTD, SAEs occurred in 3/6 patients receiving continuous afatinib 30 mg QD plus nintedanib 150 mg BID (no patient discontinued treatment due to AEs), and 3/7 patients receiving intermittent afatinib 40 mg QD plus nintedanib 150 mg BID (one patient discontinued afatinib due to AEs: dehydration, decreased appetite, diarrhoea and vomiting).
In the expansion phase, all patients experienced at least one AE, with treatment-related AEs occurring in 24 (96%) patients (Supplementary Table 1). All treatment-related AEs were Grade p3, with diarrhoea (88%), rash (56%), asthenia (52%), decreased appetite (48%) and nausea (48%) occurring most frequently. AEs led to discontinuation of afatinib in three NSCLC patients, nintedanib in two NSCLC patients, and both afatinib and nintedanib in one NSCLC patient and two pancreatic adenocarcinoma patients. SAEs were reported in 10 (40%) patients, with similar incidences in NSCLC (39%) and pancreatic adenocarcinoma (43%) patients. There were two deaths due to AEs in patients with NSCLC, neither of which were considered treatment-related; one occurred while on treatment and one post treatment (within 28 days following the last treatment administration).
Antitumour activity. Of 40 patients in the dose-escalation phase evaluable for tumour response, two PRs were observed; one in a triple-negative breast cancer patient and the other in a HNSCC patient. Both patients received intermittent afatinib 40 mg QD plus continuous nintedanib 200 mg BID (Figure 1). SD was reported as the best overall response in 60% (27/45) of patients (Figure 2A), lasting 412 weeks in eight patients. The overall DCR was 64% (29/45).
In the expansion phase, one CR and three PRs were observed in NSCLC patients treated with concomitant, continuous afatinib 30 mg QD plus nintedanib 150 mg BID (Table 4). The patient with CR was a 66-year-old male with EGFR mutation-positive NSCLC who had been heavily pretreated with five previous lines of therapy (including platinum-and taxane-based regimens with or without bevacizumab, and gefitinib). Of the three patients with PRs, all were heavily pretreated (at least two previous lines of therapy), failing prior combination chemotherapy and EGFR-TKI therapy, and one patient had EGFR mutation-positive disease. SD was observed in 61% (11/18) of NSCLC patients (lasting 412 weeks in eight patients) and 29% (2/7) of pancreatic adenocarcinoma patients; the overall DCR in NSCLC patients was 83% (15/18). Percent changes from baseline in target lesions for patients treated in the expansion phase are displayed in Figure 2B.
Pharmacokinetics. Mean trough plasma concentrations of afatinib during continuous dosing with afatinib 30 mg QD plus nintedanib 150 mg BID were similar to those observed in previous trials of afatinib 30 mg QD as monotherapy (Supplementary Figure 1). Similarly, mean trough plasma concentrations of nintedanib during dosing with nintedanib 150 mg BID plus continuous afatinib 30 mg QD were similar to those in previous nintedanib monotherapy trials. No significant drug-drug interactions between either dosing schedule of afatinib and nintedanib were observed. Table 2). Of 35 patients evaluable for tumour response, the DCR was 76% (19/25) among those with a favourable CTC count (o5 CTC/7.5 ml) at baseline, and 24% (6/25) among patients with an unfavourable CTC count at baseline. The two patients with PR had detectable CTCs at baseline that were undetectable at Day 60.

DISCUSSION
In this Phase I study in patients with advanced solid tumours, MTDs were established for both continuous and intermittent schedules of afatinib in combination with nintedanib in the dose-escalation phase: afatinib 40 mg QD intermittently (every other week) plus Other tumour types include one patient each with soft tissue sarcoma, cancer of unknown primary, biliary tree, bladder, pleura, thyroid, oesophagus and kidney. b One patient in the dose-escalation phase did not receive previous systemic therapy.
nintedanib 150 mg BID, or afatinib 30 mg QD continuously plus nintedanib 150 mg BID. On the basis of the results from two Phase II studies demonstrating a lack of antitumour activity with intermittent schedules of combined afatinib and nintedanib in patients with hormone-refractory prostate cancer (Molife et al, 2014) and advanced colorectal cancer (Bouche et al, 2011), the continuous afatinib 30 mg QD plus nintedanib 150 mg BID schedule was chosen for further evaluation in the expansion phase of the study.
The safety profile of afatinib and nintedanib combination therapy in both the dose-escalation and expansion phases was generally manageable and consistent with previous observations for the individual agents, with no new safety concerns identified (Mross et al, 2010;Yap et al, 2010;Doebele et al, 2012). In the dose-escalation phase, the most common DLTs were diarrhoea and transaminase elevations; these findings are consistent with previous combination studies of afatinib and nintedanib cancer (Bouche et al, 2011;Molife et al, 2014). In both phases of the study, the most common AEs were gastrointestinal, mainly diarrhoea. The majority of these events were Grade p3, and few study discontinuations due to diarrhoea were observed (one at the MTD of the intermittent schedule in the dose-escalation phase and three in the expansion phase); this was likely a result of early intervention and robust diarrhoea management in this study. In this context, another Phase I study of afatinib in combination with nintedanib in patients with advanced solid tumours reported a lower MTD of continuous afatinib 10 mg QD plus nintedanib 200 mg BID, which the authors attributed to excessive doselimiting diarrhoea in the absence of robust management of this AE (Gordon et al, 2015). Proactive management of diarrhoea is known to be crucial for achieving optimal clinical benefit with afatinib monotherapy .
Mean trough plasma concentrations of afatinib and nintedanib were similar to those observed in previous combination therapy and monotherapy studies (Mross et al, 2010;Yap et al, 2010;Bousquet et al, 2011;Doebele et al, 2012;Gordon et al, 2013;Marshall et al, 2013a, b). Overall, PK assessments suggest no drugdrug interactions between afatinib and nintedanib.
In this heavily pretreated population, afatinib plus nintedanib combination therapy demonstrated some antitumour activity in both the dose-escalation and expansion phases of the study. In the dose-escalation phase, one patient with triple-negative breast cancer and one with HNSCC (both on the MTD of the intermittent schedule) had a PR, and 60% of patients had SD. In the expansion phase, in patients treated with concomitant, continuous afatinib 30 mg QD plus nintedanib 150 mg BID, one CR and three PRs were observed in patients with NSCLC (with SD observed in 61% of patients); two patients with pancreatic adenocarcinoma achieved SD. These results are encouraging compared with the lack of antitumour activity observed in previous Phase II studies in patients with advanced colorectal cancer and hormone-refractory prostate cancer (Bouche et al, 2011;Molife et al, 2014). The clinical activity observed in this study suggests that the intermittent combination dosing explored in the previous trials was suboptimal, and a continuous dosing regimen may be more suitable for further development of the afatinib and nintedanib combination.
Several studies, including patients with metastatic colorectal cancer, breast cancer and castrate-resistant prostate cancer, have demonstrated an association between patient CTC counts and clinical outcomes (Cristofanilli et al, 2004;Cohen et al, 2008;de Bono et al, 2008). In an exploratory analysis of CTCs in this study, there was a higher proportion of patients with a favourable CTC count (o5 CTC/7.5 ml) among those with PR or SD compared to those with PD. These results should be interpreted with a degree of caution due to the small number of patients included in this analysis, and warrant further analysis in a larger population.
In summary, the combination of either afatinib 40 mg QD every other week plus nintedanib 150 mg BID, or continuous afatinib Poor compliance for one patient and treatment exposure for less than 21 days due to consent withdrawal for another patient. b Premature discontinuation due to clinical progression for one patient.